Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST-IT: ABL-101 and Oxygen in Acute Stroke
NCT03463551Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised trial of perfluoro-tert-butylcyclohexane in ischemic stroke (2 cohorts), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Safety and tolerability of 3 dose levels of ABL-101 and supplemental oxygen at 7 days. Status: unknown.
02
Drugs
perfluoro-tert-butylcyclohexane
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03463551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463551.